COMMUNIQUÉS West-GlobeNewswire

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
29/09/2025
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for [...]
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
29/09/2025
RAPT on track to initiate trial this year SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on [...]
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
29/09/2025
Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits 1 as of June 30, 2025 Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités
29/09/2025
Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme 1 à 24,6 millions d’euros au 30 juin 2025 Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du [...]
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
29/09/2025
A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy [...]
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
29/09/2025
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage [...]
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
29/09/2025
Next generation sustained-release formulations for a variety of peptides Executive summary first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for [...]
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
29/09/2025
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
28/09/2025
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company [...]

Pages